Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gestational breast cancer: distinctive molecular and clinico-epidemiological features.
de la Haba-Rodríguez JR, Mínguez P, Rojo F, Martín M, Alba E, Servitja S, Prat A, Pérez-Fidalgo JA, Gavilá J, Morales C, Rodriguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez MT, Blanch S, Caballero R, Martín N, Pollán M, Guerrero-Zotano A, Bermejo B. de la Haba-Rodríguez JR, et al. Among authors: servitja s. J Mammary Gland Biol Neoplasia. 2024 Nov 8;29(1):18. doi: 10.1007/s10911-024-09571-3. J Mammary Gland Biol Neoplasia. 2024. PMID: 39514034 Free PMC article.
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis.
Vazquez JC, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, Lluch A, Martin M, Rodriguez-Lescure A, Sola I, Bonfill X, Urrutia G, Sanchez-Rovira P. Vazquez JC, et al. Among authors: servitja s. Clin Transl Oncol. 2023 Apr;25(4):941-958. doi: 10.1007/s12094-022-02998-2. Epub 2022 Nov 22. Clin Transl Oncol. 2023. PMID: 36417083 Review.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, Ruiz-Borrego M, Bermejo B, Guerrero Á, Ramos M, Santaballa A, Muñoz M, Cruz J, Lopez-Tarruella S, Chacón JI, Álvarez I, Martínez P, Miralles JJ, Polonio Ó, Jara C, Aguiar-Bujanda D. Martín M, et al. Among authors: servitja s. Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20. Breast Cancer Res Treat. 2023. PMID: 37338729 Free PMC article. Review.
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Santana-Hernández S, et al. Among authors: servitja s. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. J Exp Clin Cancer Res. 2024. PMID: 38167224 Free PMC article.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Rojo F, et al. Among authors: servitja s. Ann Oncol. 2012 May;23(5):1156-1164. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9. Ann Oncol. 2012. PMID: 21908496 Free article.
SEOM clinical guidelines in early stage breast cancer (2018).
Ayala de la Peña F, Andrés R, Garcia-Sáenz JA, Manso L, Margelí M, Dalmau E, Pernas S, Prat A, Servitja S, Ciruelos E. Ayala de la Peña F, et al. Among authors: servitja s. Clin Transl Oncol. 2019 Jan;21(1):18-30. doi: 10.1007/s12094-018-1973-6. Epub 2018 Nov 15. Clin Transl Oncol. 2019. PMID: 30443868 Free PMC article.
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Antón A, Casas M, Csöszi T, Murillo L, Morales S, Calvo L, Lang I, Alba E, de la Haba-Rodriguez J, Ramos M, López IÁ, Gal-Yam E, Garcia-Palomo A, Alvarez E, González-Santiago S, Rodríguez CA, Servitja S, Corsaro M, Rodrigálvarez G, Zielinski C, Martín M. Kahan Z, et al. Among authors: servitja s. Eur J Cancer. 2021 Oct;156:70-82. doi: 10.1016/j.ejca.2021.07.004. Epub 2021 Aug 20. Eur J Cancer. 2021. PMID: 34425406 Free article. Clinical Trial.
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer.
Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M. Muntasell A, et al. Among authors: servitja s. Cancer Immunol Res. 2019 Aug;7(8):1280-1292. doi: 10.1158/2326-6066.CIR-18-0896. Epub 2019 Jun 12. Cancer Immunol Res. 2019. PMID: 31189644
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F. Dalmases A, et al. Among authors: servitja s. Oncotarget. 2014 Jan 15;5(1):196-210. doi: 10.18632/oncotarget.1556. Oncotarget. 2014. PMID: 24344116 Free PMC article.
Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma.
Rojo F, González-Pérez A, Furriol J, Nicolau MJ, Ferrer J, Burgués O, Sabbaghi M, González-Navarrete I, Cristobal I, Serrano L, Zazo S, Madoz J, Servitja S, Tusquets I, Albanell J, Lluch A, Rovira A, Eroles P. Rojo F, et al. Among authors: servitja s. Br J Cancer. 2016 Jul 26;115(3):322-31. doi: 10.1038/bjc.2016.204. Epub 2016 Jul 12. Br J Cancer. 2016. PMID: 27404455 Free PMC article.
65 results